114 related articles for article (PubMed ID: 32663249)
1. Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.
Li H; Dai H; Shi T; Cheng X; Sun M; Chen K; Wang M; Wei Q
Carcinogenesis; 2020 Sep; 41(9):1229-1237. PubMed ID: 32663249
[TBL] [Abstract][Full Text] [Related]
2. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.
Zeng Y; Li TL; Zhang HB; Deng JL; Zhang R; Sun H; Wan ZR; Liu YZ; Zhu YS; Wang G
Pharmacogenomics; 2019 Feb; 20(3):179-188. PubMed ID: 30672383
[TBL] [Abstract][Full Text] [Related]
4. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
6. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
Permuth-Wey J; Fulp WJ; Reid BM; Chen Z; Georgeades C; Cheng JQ; Magliocco A; Chen DT; Lancaster JM
Int J Cancer; 2016 Feb; 138(3):612-9. PubMed ID: 26264211
[TBL] [Abstract][Full Text] [Related]
7. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
8. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
9. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
10. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
French JD; Johnatty SE; Lu Y; Beesley J; Gao B; Kalimutho M; Henderson MJ; Russell AJ; Kar S; Chen X; Hillman KM; Kaufmann S; Sivakumaran H; O'Reilly M; Wang C; Korbie DJ; ; ; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching PA; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Pisterer J; Hillemanns P; Nakanishi T; Yatabe Y; Goodman MT; Lurie G; Matsuno RK; Thompson PJ; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan JM; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut JM; Iversen E; Weber RP; Brennan D; Berchuck A; Pharoah P; Harnett P; Norris MD; Haber M; Goode EL; Lee JS; Khanna KK; Meyer KB; Chenevix-Trench G; deFazio A; Edwards SL; MacGregor S;
Oncotarget; 2016 Feb; 7(6):6353-68. PubMed ID: 26840454
[TBL] [Abstract][Full Text] [Related]
11. Clinical relationships between the rs2212020 and rs189897 polymorphisms of the
Liu J; Liu T; Liang L; He J; Zhang M; Ge Y; Liao S; Zhou Y; Zhang K
J Genet; 2019 Mar; 98():. PubMed ID: 30945681
[TBL] [Abstract][Full Text] [Related]
12. Functional genetic variants of RUVBL1 predict overall survival of Chinese patients with epithelial ovarian cancer.
Li H; Tong X; Xu Y; Wang M; Dai H; Shi T; Sun M; Chen K; Cheng X; Wei Q
Carcinogenesis; 2019 Oct; 40(10):1209-1219. PubMed ID: 31083717
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
14. A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients.
Zhao J; Wu J; Zuo W; Kang S; Li Y
Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():183-189. PubMed ID: 33147530
[TBL] [Abstract][Full Text] [Related]
15. Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.
Xu Y; Cheng L; Dai H; Zhang R; Wang M; Shi T; Sun M; Cheng X; Wei Q
J Cell Mol Med; 2018 Oct; 22(10):4975-4984. PubMed ID: 30055028
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
17. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
[TBL] [Abstract][Full Text] [Related]
18. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women.
Shi TY; Jiang Z; Jiang R; Yin S; Wang MY; Yu KD; Shao ZM; Sun MH; Zang R; Wei Q
Tumour Biol; 2015 Sep; 36(9):6919-27. PubMed ID: 25854172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]